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The combined activity of three transcription factors
can reprogram adult cells into induced pluripotent
stem cells (iPSCs). However, the transgenic methods
used for delivering reprogramming factors have
raised concerns regarding the future utility of the
resulting stem cells. These uncertainties could be
overcome if each transgenic factor were replaced
with a small molecule that either directly activated
its expression from the somatic genome or in some
way compensated for its activity. To this end, we
have used high-content chemical screening to iden-
tify small molecules that can replace Sox2 in reprog-
ramming.We show that one of thesemolecules func-
tions in reprogramming by inhibiting Tgf-b signaling
in a stable and trapped intermediate cell type that
forms during the process. We find that this inhibition
promotes the completion of reprogramming through
induction of the transcription factor Nanog.
INTRODUCTION
Retroviral transduction with three genes, Sox2, Oct4, and Klf4,
can directly reprogram somatic cells to a pluripotent stem cell
state (Okita et al., 2007; Takahashi et al., 2007b). Unfortunately,
the resulting induced pluripotent stem cells (iPSCs) are subop-
timal for applications in transplantation medicine and disease
modeling because both the viral vectors used for gene transfer
and the reprogramming factors they encode are oncogenic
(Hacein-Bey-Abina et al., 2003; Nakagawa et al., 2008; Thrasher
and Gaspar, 2007).
One potential solution is to identify small molecules that can
efficiently reprogram cells and produce unmodified iPSC lines
better suited for downstream applications as a result. Identifica-
tion of such compounds would allow reprogramming that would
not be impeded by the laborious nature of protein transduction or
the safety concerns surrounding transgenic approaches (Kaji
et al., 2009; Kim et al., 2009; Okita et al., 2008).CSeveral small molecules that catalyze reprogramming have
already been described. Compounds that alter chromatin struc-
ture, including the DNA methyltransferase inhibitor 5-aza-cyti-
dine (AZA) and the histone deacetylase (HDAC) inhibitor valproic
acid (VPA), can increase reprogramming efficiency and even
reduce the number of factors required for reprogramming
(Huangfu et al., 2008a; Huangfu et al., 2008b; Mikkelsen et al.,
2008; Shi et al., 2008b) . Treatment with these inhibitors presum-
ably lowers the barrier to activation of endogenous pluripotency-
associated genes. However, Oct4 and Sox2 not only activate
genes required for pluripotency, they also function to repress
genes promoting differentiation. It is therefore unlikely that this
class of small molecules would be sufficient to completely
replace the transgenic factors. As a result, there remains a
need to identify novel small molecules that can function in
reprogramming.
Here, we report the discovery of compounds that can replace
the central reprogramming factor Sox2. We demonstrate that
one of these chemicals specifically acts by inhibiting Tgf-b
signaling. Interestingly, this compound does not act by inducing
Sox2 expression in the target fibroblasts. Instead, we show that it
enables reprogramming through the induction of Nanog tran-
scription in a stable, partially reprogrammed cell type that
accumulates in the absence of Sox2.
RESULTS
A Screen for Chemical Mediators of Reprogramming
To identify small molecules that function in reprogramming, we
transduced fibroblasts with viral vectors encoding Oct4, Klf4,
and cMyc and then screened for compounds that allowed for
reprogramming in the absence of Sox2. We favored this
approach because it was unbiased with respect to the mecha-
nism by which a given chemical could function and would not
only deliver chemical compounds with translational utility but
also provide novel insights into the mechanisms controlling
reprogramming.
Activation of an Oct4::GFP reporter gene in colonies with an
embryonic stem cell (ESC) morphology has been shown to be
a stringent assay for reprogramming (Meissner et al., 2007). Inell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc. 491
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A Tgf-b Inhibitor Replaces Sox2 in Reprogrammingmouse embryonic stem cell (mESC) culture medium supple-
mented with VPA, retroviral transduction of 7500 Oct4::GFP
transgenic mouse embryonic fibroblasts (MEFs) with Oct4,
Klf4, cMyc, and Sox2 (Boiani et al., 2004) routinely generated
100–200 GFP+ colonies (Figure 1A). In contrast, we observed
no GFP+ colonies when Sox2 was omitted (Figure 1A). We
used this robust difference to identify small molecules that can
replace Sox2.
To facilitate the identification of cellular targets and signaling
pathways affectedby any compoundswediscovered,weutilized
a library of molecules with known pharmacological targets. We
transduced Oct4::GFP MEFs with Oct4, Klf4, and cMyc and
Figure 1. Identification of Small Molecules That Replace of Sox2
(A)Oct4::GFP+ colonies form readily inOct4, Klf4, cMyc, and Sox2-infected MEF cultures and do not form inOct4-,Klf4-, and cMyc-infected MEF cultures. Scale
bars represent 500 mm.
(B) Overview of chemical screen for replacement of Sox2.
(C) A P0 colony from Oct4-, Klf4-, and cMyc-infected MEFs + RepSox that displays a mESC-like morphology and is Oct4::GFP+. Scale bars represent 200 mm.
(D) Number of Oct4::GFP+ colonies detected for each hit in the primary screen after transduction of Oct4, Klf4, and cMyc and VPA treatment.
(E) Chemical structures of E-616452, E-616451, and EI-275, with the optimal concentrations for reprogramming listed.
(F) Quantification of small-molecule replacement of Sox2 in Oct4-, Klf4-, and cMyc-infected MEFs with and without VPA treatment. The error bars denote the
standard error derived from quantification of three separate wells of cells.
(G) Sox2 replacement by RepSox is not dependent on cMyc (no VPA treatment). The error bars denote the standard error derived from quantification of three
separate wells of cells.492 Cell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc.
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we added one of 800 distinct compounds for 7–11 days and also
treated eachwell with 2mMVPA for the first 7 days (Figure 1B). It
was our hope that this approach would allow us to identify both
compounds that required chromatin remodeling to induce
reprogramming (Huangfu et al., 2008a) and compounds that
did not. After 16 days, we scored each well for the presence of
GFP+ colonies with a mESC-like morphology (Figure 1C) and
identified three independent hit compounds (Figure 1D). Two of
these compounds were distinct transforming growth factor-
b receptor 1 (Tgfbr1) kinase inhibitors (E-616452 and E-616451
[Figure 1E] [Gellibert et al., 2004]), whereas the third was a Src-
family kinase inhibitor (EI-275 [Figure 1E] [Hanke et al., 1996]).
Efficient Small-Molecule Replacement of Sox2
Next, we optimized the effective concentration for each hit mole-
cule (Figure S1 available online) and quantified the efficiency at
which it synergized with VPA to replace Sox2. When 1500
MEFs were transduced with only Oct4, Klf4, and cMyc and then
treated with VPA, we did not observe GFP+ colonies (Figure 1F).
However, the addition of E-616452 (25 mM), E-616451 (3 mM), or
EI-275 (3 mM) led to the formation of GFP+ colonies with an ESC
morphology at a rate that was comparable to transduction with
Sox2 (Figure 1F).
Given that the three compounds were identified in the pres-
ence of VPA, we next determined whether these molecules
were dependent on this HDAC inhibitor for their reprogramming
activities. We found that E-616451 and EI-275 could not induce
the appearance of GFP+ colonies in the absence of VPA (Fig-
ure 1F), whereas E-616452 could do so and at a rate that was
similar to a positive control transduced with the Sox2 retrovirus
(Figure 1F).
Although cMyc does increase the efficiency of reprogram-
ming, it is not required for the generation of iPSCs (Nakagawa
et al., 2008). Because the elimination of cMyc is an important
step toward reducing the risk of tumor formation, we tested
whether E-616452 could function in the absence of this onco-
gene. When added to MEFs transduced with only Oct4 and
Klf4, E-616452 induced the formation of GFP+ colonies with an
efficiency similar to viral Sox2 (Figure 1G).
Previous reports on smallmolecules that affect reprogramming
have focused on MEFs or neural stem cells (NSCs). These cells
may be reprogrammed more easily because of either their prolif-
erative capacity or their expression of iPSC factors (Huangfu
et al., 2008a; Shi et al., 2008a; Shi et al., 2008b). However,
it may be that chemical modulation of gene expression is
cell-type specific, and we therefore determined whether the
reprogramming compound we identified functioned in a more
patient-relevant cell type. When we infected adult tail tip fibro-
blasts with Oct4, Klf4, and cMyc alone, we did not observe
Oct4::GFP+ colonies. However, when we added E-616452, we
readily observed reprogramming (Figure S2A). The resulting
Oct4::GFP+ colonies could be expanded into cell lines that main-
tained homogeneous Oct4::GFP expression and self-renewed
similarly to mESC and 4-factor control iPSC lines (Figure S2B).
Because it could efficiently replace transgenic Sox2 in the
absenceof VPAand cMyc, aswell as in both embryonic and adult
fibroblasts, we chose to further characterize E-616452 and
named it RepSox, for Replacement of Sox2.CeRepSox-Reprogrammed Cells Are iPSCs
Investigation of self-renewal capacity (Figure 2A), gene expres-
sion program, and pluripotency demonstrated that Oct4::GFP+
cells induced by the RepSox replacement of Sox2 were bona
fide iPSCs. PCR with primers specific to the Oct4, Klf4, cMyc,
and Sox2 transgenes confirmed that this cell line did not harbor
transgenic Sox2 (Figure S3A). Chromosomal analysis indicated it
was karyotypically normal (Figure S3B).
The Oct4::GFP+ cells coexpressed alkaline phosphatase (Fig-
ure S3C) and the endogenous alleles of the Nanog and Sox2
genes, suggesting pluripotency had been established (Fig-
ure 2B). The global transcriptional profile of cells reprogrammed
with RepSox was similar to that of an iPSC line produced with all
four transgenes and as similar to those ofmESCs (Pearson corre-
lation coefficient = 0.95–0.97) as two distinct mESC lines profiles
were to each other (Pearson correlation coefficient = 0.96)
(Figure 2C, Figure S3D, and Table S1). The profile differed signif-
icantly from that of the somatic MEFs (Figure 2C).
Cells produced with RepSox could readily form both embryoid
bodies and teratomas that contained differentiated cell types of
the three distinct embryonic germ layers (Figure 2E and Fig-
ure S4A). In addition, we observed that these cells could respond
to directed differentiation signals in vitro and robustly differen-
tiate into Hb9+/Tuj1+ motor neurons (Figure 2D and Figure S5).
In order to more definitively confirm the pluripotency of cells
reprogrammed with RepSox, we tested their ability to contribute
to chimeric embryos in vivo. We labeled cells with a lentiviral
transgene encoding the dTomato red fluorescent protein and
injected them into blastocysts. Both embryos and adult mice
with significant contribution from the iPSCs were obtained (Fig-
ures 2F and 2G). Although adult mice with high contribution from
the iPSCs were observed, we found it difficult to assess the
contribution of these cells to the germline because the majority
of animals developed tumors at or before the time of sexual
maturity. However, we did observe that the reprogrammed cells
could contributeOct4::GFP+ cells to the genital ridges of embry-
onic chimeras, demonstrating contribution of these pluripotent
cells to the germline (Figure 2H). Together, these results demon-
strate that the RepSox-reprogrammed cells are indeed iPSCs.
RepSox Can Replace Sox2 and c-Myc by Inhibiting
Tgf-b Signaling
Previous studies with RepSox suggest that it can act as an inhib-
itor of the Tgfbr1 kinase (Gellibert et al., 2004). Therefore, we
investigatedwhether themechanism bywhich RepSox functions
to replace Sox2 is through the inhibition of Tgf-b signaling. If
Tgfbr1 is the functional target of RepSox, then a structurally
unrelated inhibitor of Tgf-b signaling or depletion of Tgf-b ligands
from the culture medium might also replace Sox2. The small
molecule SB431542 (Figure 3A) is known to inhibit Tgfbr1 kinase
and is structurally distinct from RepSox (Inman et al., 2002).
When we treated fibroblasts transduced with Oct4, Klf4, and
cMyc with 25 mM SB431542, we observed 10 GFP+ colonies
per 7500 cells plated (Figure 3B). Likewise, when we transduced
fibroblasts in the presence of either an antibody that neutralized
a variety of Tgf-b ligands (R&D Systems, AB-100-NA) or an anti-
body specific to Tgf-b II (R&D Systems, AB-12-NA), Oct4::GFP+
colonies were generated (Figure 3B). In contrast, we observed
no GFP+ colonies in transductions without these Tgf-b inhibitors.ll Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc. 493
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the mechanism by which RepSox replaces Sox2 in reprogram-
ming is through the inhibition of Tgf-b signaling.
Our goal was to identify molecules that specifically replace
Sox2 instead of generally increasing reprogramming efficiency.
If RepSox acts specifically to replace Sox2, then we would not
expect it to stimulate reprogramming in the presence of trans-
genic Sox2. When RepSox- or Tgf-b antibody-treated MEFs
were transduced with Oct4, Klf4, cMyc, and Sox2, we observed
less than a 2-fold increase in the number of GFP+ colonies over
the untreated controls (Figures 3C and 3D). The magnitude by
which RepSox stimulated reprogramming in this context was
significantly less than the 10-fold increase that we observed after
treatment with VPA, a compound thought to increase reprog-
ramming efficiency (Figure 1F).
In order to further investigate the specificity of Sox2 replace-
ment by RepSox, we tested the ability of this molecule to individ-
ually replace Oct4, Klf4, and cMyc in reprogramming. We found
Figure 2. RepSox-Reprogrammed Cells Are Pluripotent
(A) An Oct4::GFP+ iPSC line that was derived from a culture of RepSox-treated Oct4, Klf4, and cMyc-infected MEFs (OKM + RepSox line 1) displays the
characteristic mESC-like morphology and self-renewal properties. Passage 11 is shown. Scale bars represent 500 mm.
(B) Antibody staining of OKM + RepSox line 1 cells shows that they express markers of pluripotent stem cells Sox2 and Nanog. Scale bars represent 100 mm.
(C) Microarray scatter plots showing that the global gene expression profile of OKM + RepSox line 1 is highly similar to that of mESC line V6.5 and very different
from that of somatic MEFs.
(D) Motor neurons differentiated in vitro from OKM + RepSox line 1. The scale bar represents 200 mm.
(E) Teratomas containing cells of all three germ layers formed by injection of OKM + RepSox line 1 cells into nude mice.
(F) E12.5 chimeric mouse embryo (left, versus nonchimeric littermate on the right) showing a high amount of contribution from OKM + RepSox line 1 cells consti-
tutively expressing the dTomato red fluorescent protein.
(G) Eight-week-old chimeric mouse formed by injection of OK + RepSox line 1 cells (C57BL6 genetic background) into an ICR blastocyst.
(H) Oct4::GFP+ cells derived from an OKM + RepSox cell line are present in the genital ridge of a male embryo at 13.5 days postcoitum (dpc).494 Cell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc.
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either Oct4 or Klf4, even in the presence of VPA (Figure 3E). In
contrast, we found that RepSox did increase the number of
Oct4::GFP+ colonies by 20-fold in the absence of cMyc, thereby
fully replacing it in reprogramming (Figure 3F). In addition, the
structurally distinct Tgf-b inhibitor SB431542 and a Tgf-b-
specific neutralizing antibody both increased reprogramming
efficiency in the absence of cMyc (Figure 3G). From these exper-
iments, we conclude that RepSox enables the replacement of
the reprogramming activities provided by both transgenic Sox2
and cMyc. In both cases, these complementing activities seem
to be mediated through the inhibition of Tgf-b signaling.
RepSox Replaces Sox2 by Acting on Intermediates
Formed During the Reprogramming Process
The development of cocktails of small molecules that can effec-
tively reprogram somatic cells may require a detailed knowledge
of the mechanism and kinetics by which each compound acts.
Therefore, we determined the optimal duration of time by which
inhibition of Tgf-b signaling with RepSox can help induce reprog-
ramming.
Initially, we pretreated MEFs with RepSox, applying the chem-
ical for 3 days, and then removed it at the time of transduction
with Oct4, Klf4, and cMyc. In these experiments, no Oct4::GFP+
colonies were formed (Figure 4A), suggesting that RepSox does
not act on the initial somatic cells to replace Sox2. Consistent
with this result, we did not detect a significant increase in the
expression of endogenous Sox2 or closely related Sox family
members upon RepSox treatment (Figure S6A). In addition,
RepSox treatment did not decrease the expression of the
mesenchymal gene Snai1 (Figure S6B), which is downregulated
5- to 40-fold by transduction of the four reprogramming factors
(Mikkelsen et al., 2008). Thus, RepSox does not destabilize the
pre-existing MEF transcriptional program.
In contrast, we found that RepSox did increase by 5-fold the
expression of L-Myc, a close homolog of cMyc that can function-
ally replace it in reprogramming (Nakagawa et al., 2008) (Fig-
ure S6C). Together, these data suggest that although RepSox
Figure 3. RepSox Specifically Replaces
Sox2 by Inhibiting Tgf-b Signaling
(A) Chemical structure of SB431542, an inhibitor of
Tgfbr1 activity.
(B) Inhibition of Tgf-b signaling by treatment of
Oct4-, cMyc-, and Sox2-infected MEFs with
SB431542 or TGF-b neutralizing antibodies
replaces Sox2.
(C) RepSox does not increase the efficiency of
Oct4::GFP+ colony induction in Oct4-, Klf4-,
cMyc-, and Sox2-infected MEFs. The error bars
denote the standard error derived from quantifica-
tion of three separate wells of cells.
(D) Inhibition of Tgf-b signaling by TGF-b neutral-
izing antibodies does not increase the efficiency
of Oct4::GFP+ colony induction in Oct4-, Klf4-,
cMyc-, and Sox2-infected MEFs. The error bars
denote the standard error derived from quantifica-
tion of three separate wells of cells.
(E) RepSox does not replace transgenic Oct4 or
transgenic Klf4 in reprogramming. We observed
no Oct4::GFP+ colonies in RepSox-treated Klf4-,
cMyc-, and Sox2-infected MEFs or Oct4-, cMyc-,
Sox2-infected MEFs out of 30,000 cells plated
both with and without VPA treatment. We routinely
observe 30–40 Oct4::GFP+ colonies when we
plate the same number of Oct4-, Klf4-, and
cMyc-infected MEFs and treat them with RepSox.
The error bars denote the standard error derived
from quantification of three separate wells of cells.
(F) RepSox can replace cMyc in reprogramming.
Cells were transduced with Oct4, Klf4, and cMyc
and treated with RepSox continuously starting at
day 5 postinfection. The error bars denote the
standard error derived from quantification of two
separate wells of cells.
(G) Inhibition of Tgf-b signaling can replace cMyc
in reprogramming. Cells were transduced with
Oct4, Klf4, and cMyc and treated with inhibitors
of Tgf-b signaling continuously starting at day 5
postinfection. The error bars denote the standard
error derived from quantification of two separate
wells of cells.Cell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc. 495
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A Tgf-b Inhibitor Replaces Sox2 in Reprogrammingprobably functions at the level of the initial somatic cell popula-
tion to replace cMyc, it does not act on the starting MEF popula-
tion to replace Sox2.
Because RepSox did not seem to act directly on the fibro-
blasts to replace Sox2, we investigated whether it functioned
on intermediates that arose during reprogramming. To address
this question, we varied both the duration and timing of RepSox
treatment in order to determine when it was most effective. First,
we transduced 7500 MEFs withOct4, Klf4, and cMyc, waited for
4 days, and subsequently treated cultures with RepSox for 3, 6,
9, or 18 additional days. Although a short 3 day treatment from
days 4–7 induced a small number of Oct4::GFP+ colonies, the
9-day treatment from days 4–13 yielded the most Oct4::GFP+
colonies (Figure 4A).
Figure 4. A Short Pulse of RepSox Is Sufficient for Sox2 Replace-
ment and Most Effective at Later Time Points after Infection
(A) Graph showing the number of Oct4::GFP+ colonies induced by various
timings of RepSox treatment of Oct4-, Klf4-, and Sox2-infected MEFs in
mESC medium. Colonies were counted at 24 days postinfection. Shown are
average colony numbers ± the standard deviation. The standard deviation
was derived from quantification of two separate wells.
(B) Time course of RepSox treatment showing the number ofOct4::GFP+ colo-
nies induced by a 24 hr pulse of RepSox on Oct4-, Klf4-, and Sox2-infected
MEFs in serum-free mESC medium with knockout serum replacement (KSR
mESC). Colonies were counted at 24 days postinfection. The error bars denote
the standard error derived from quantification of three separate wells of cells.496 Cell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier IncNext, we varied the timing at which we initiated RepSox treat-
ment, by administering the compound beginning at day 4, 7, 10,
13, or 16 after transduction. We found that delaying the start of
RepSox treatment increased its reprogramming potency, with
optimal treatment beginning at 10 days posttransduction (Fig-
ure 4A). Together, these results suggest that RepSox treatment
is most effective between days 7–12 posttransduction.
To more precisely define the optimal treatment window, we
determined the minimal duration of treatment required to induce
reprogramming.We found that a treatment as short as only 1 day
was sufficient for inducing detectable reprogramming (Fig-
ure 4B). Delaying this short treatment yielded more reprog-
rammed colonies, with a sharp increase at day 11 (Figure 4B).
These results indicate that RepSox is most effective at replacing
Sox2 during days 10–11 after transduction and that therefore
cultures of Oct4, Klf4, and cMyc-transduced MEFs give rise to
intermediates capable of responding to RepSox treatment.
These intermediates appear at day 4 posttransduction and
peak at days 10–11.
Interestingly, when we tracked the timing of the initial appear-
ance of reprogrammed colonies as a function of the timing of
RepSox administration, we found that regardless of whether
we began treatment at day 7 or day 10 posttransduction,
Oct4::GFP+ colonies first appeared at day 14 (Figure S7). This
suggests that RepSox may not always be the rate-limiting step
in this reprogramming process and that other, RepSox-indepen-
dent events take place during the formation of the RepSox-
responsive intermediates.
RepSox-Responsive Cell Lines
Our finding that a 24 hr pulse of RepSox can replace Sox2 (Fig-
ure 4B) differs strikingly from the 5–10 day period of transgene
expression normally required (Sridharan et al., 2009; Wernig
et al., 2007) and suggests that RepSox could trigger a switch
activating reprogramming. If RepSox acts to flip a switch in semi-
stable intermediate cell types that accumulate in the absence of
retroviral Sox2 expression, we reasoned that it might also be
possible to culture these responsive intermediates for prolonged
periods of time. In contrast, if RepSox acts during a critical
window on very transient intermediates, this might not be
possible. To distinguish between these models, we transduced
Oct4::GFP MEFs with Oct4, Klf4, and cMyc, waited 10-14
days, and subsequently clonally expanded ten iPSC-like, GFP-
negative colonies (Figure 5A). These cell lines continued to
proliferate for at least four passages and often maintained an
iPSC-like morphology (Figure 5A), but never further activated
expression of Oct4::GFP. However, when we treated these cell
lines with a 48 hr pulse of RepSox, 5%–10% of the colonies in
two of the ten lines became Oct4::GFP+ (Figures 5A and 5B).
These results demonstrate that partially reprogrammed cells
can accumulate in the absence of Sox2 and that some, but not
all, of these cells can be clonally expanded and cultured for pro-
longed periods while maintaining responsiveness to RepSox.
As we had shown that this particular reprogramming molecule
seems to replace Sox2 through the inhibition of Tgf-b signaling,
we sought to determine whether RepSox treatment affected
Tgf-b signal transduction pathways in these responsive cell lines.
To this end, we determined the levels of phosphorylated Smad3
by western blotting in cell line OKM 10 both with and without.
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A Tgf-b Inhibitor Replaces Sox2 in ReprogrammingRepSox treatment. Without RepSox treatment, we detected
relatively high levels of phosphorylated Smad3, suggesting that
Tgf-b signaling was active (Figure 5C). In contrast, treatment
with 25 mM RepSox almost completely eliminated Smad3 phos-
phorylation (Figure 5C), indicating that RepSox strongly inhibited
Tgf-b signaling in these cells.
Because an increase in cell proliferation can also increase
reprogramming efficiency (Hong et al., 2009) and possibly
contribute to the replacement of transgenic Sox2, we measured
the proliferation rate of partially reprogrammed OKM 10 cells
both with and without RepSox. Treatment with RepSox
decreased the proportion of cells in G2/M phase of the cell cycle
(Figure 5D), indicating it does not increase the proliferation rate of
these partially reprogrammed cells.
Cells that Respond to RepSox Treatment Are Distinct
from Previously Described Intermediates
It has been shown that certain nonpluripotent, partially reprog-
rammed cell lines derived from MEFs transduced with Oct4,
Klf4, cMyc, and Sox2 can be fully reprogrammed with AZA or
a combination of chemical inhibitors of glycogen synthase kinase
3b (GSK-3b) and the Mek signaling pathway (2i conditions)
(Mikkelsen et al., 2008; Silva et al., 2008). If the RepSox-respon-
sive cell lines generated by overexpression of Oct4, Klf4, and
cMyc are similar to these four-factor cell lines, then they should
also be reprogrammed by AZA or 2i. However, when we treated
the ten stable intermediate lines with either AZA or 2i for 48 hr,
we found that none became reprogrammed (Figure 5B), indi-
cating that the RepSox-responsive stable intermediates are
distinct from partially reprogrammed cell lines described previ-
ously (Mikkelsen et al., 2008; Silva et al., 2009). Consistent with
these results, in vitro assays of kinase activity revealed that
RepSox does not inhibit the targets of the 2i cocktail (Table S2).
It occurred to us that some nonpluripotent cells derived from
MEFs transduced with Oct4, Klf4, cMyc, and Sox2 could poten-
tially be held in a nonpluripotent state because of inappropriate
levels of transgene expression and therefore might also be
responsive to RepSox treatment. To test this hypothesis, we
transduced Oct4::GFP MEFs with Oct4, Klf4, cMyc, and Sox2,
then picked and clonally expanded nine GFP-negative colonies
at day 14 after transduction (Figure S8). After treatment with
RepSox, five of the nine cell lines yielded reprogrammed colo-
nies, with 2%–33% of the colonies in each line becoming
Oct4::GFP+ (Figure 5F and Figure S8). These results indicate
Figure 5. Stable Intermediates Can Be Re-
programmed by RepSox
(A) Stable Oct4::GFP-negative cell lines derived
from Oct4::GFP-negative colonies in Oct4-, Klf4-,
and cMyc-infected MEF cultures can be reprog-
rammed by RepSox. Scale bars in ‘‘OKM line
10 + RepSox’’ panels represent 500 mm; all other
scale bars represent 200 mm.
(B) Two of ten stable, nonpluripotent intermediate
cell lines derived from MEFs transduced with
Oct4, Klf4, and cMyc can be reprogrammed with
RepSox treatment, but none can be reprog-
rammed with AZA treatment.
(C) Western blot for phospho-Smad3 showing that
RepSox inhibits Tgf-b signaling in line OKM 10
(OKM 10) cells.
(D) RepSox does not increase the proliferation of
OKM 10 cells. The error bars denote the standard
error derived from quantification of two separate
wells of cells.
(E) Line OKM 10 can be reprogrammed with
RepSox treatment but not with AZA or 2i, indi-
cating it is distinct from cell lines that can be re-
programmed by AZA or 2i. The error bars denote
the standard error derived from quantification of
three separate wells of cells.
(F) Stable Oct4::GFP-negative cell lines derived
from Oct4::GFP-negative colonies in Oct4-, Klf4-,
cMyc-, and Sox2-infected MEF cultures can be
reprogrammed by RepSox or by AZA, but lines
responsive to RepSox are not responsive to AZA
alone and lines responsive to AZA are not respon-
sive to RepSox alone, indicating the presence of
two different types of stable intermediates in the
reprogramming cultures.Cell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc. 497
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(A) RepSox treatment of RepSox-responsive line OKMS 6 strongly increasesNanogmRNA levels. Data were generated by microarray analysis and are relative to
untreated controls. Nanog is induced more quickly and more significantly than Sox2, indicating it is upregulated before fully reprogrammed cells form. The error
bars denote the standard error derived from quantification of three separate wells of cells.
(B) RT-PCR analysis showing that inhibition of Tgf-b signaling increases Nanog expression in the RepSox-responsive intermediate line OKMS 7.
(C) A pulse of RepSox induces a persistent increase in Nanog expression in the RepSox-responsive intermediate line OKM 10. OKM 10 cells were treated with
25 mM RepSox for 48 hr and RNA samples were taken at 0, 48, and 96 hr (48 hr after removal of RepSox) and analyzed by RT-PCR.
(D) shRNA-mediated knockdown of Nanog in OKM 10 cells inhibits replacement of Sox2 by RepSox. The error bars denote the standard error derived from
quantification of two separate wells of cells.
(E) Pictures of reprogrammed Oct4::GFP+ colonies induced by Sox2 (A) or Nanog (B) transduction of line OKM 10. Scale bars represent 200 mm.
(F) Nanog transduction can reprogram line OKM 10 at an efficiency similar to that of Sox2 transduction. The error bars denote the standard error derived from
quantification of three separate wells of cells.498 Cell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc.
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Klf4, and cMyc, certain incompletely reprogrammed cells gener-
ated by Oct4, Klf4, cMyc, and Sox2 transduction can also be re-
programmed by RepSox.
Next, in order to determine whether these RepSox-responsive
intermediate cell lines derived after Oct4, Klf4, cMyc, and Sox2
transduction were similar to or distinct frompreviously described
partially reprogrammed cell lines (Mikkelsen et al., 2008), we
applied AZA to all nine lines. After 48 hr of AZA treatment and
12 subsequent days in culture, none of the RepSox-responsive
cell lines expressed Oct4::GFP (Figure 5F). However, one of
the lines that had been refractory to RepSox treatment did
express Oct4::GFP after AZA treatment, indicating that it had
undergone complete reprogramming (Figure 5F). Together,
these results show that there are a variety of intermediates that
can form after retroviral transduction and that they vary in their
responsiveness to reprogramming molecules.
RepSox Replaces Sox2 by Inducing Nanog Expression
The causal molecular events that drive reprogramming are diffi-
cult to detect because of the low efficiency at which somatic
cells are successfully reprogrammed (Amabile and Meissner,
2009). However, when we administered RepSox to cell lines
that had been partially reprogrammed by retroviral transduction,
Oct4::GFP expression was induced in up to 33% of the resulting
colonies (Figure 5F). We used this more efficient reprogramming
system to identify the changes in gene expression induced by
RepSox that enable it to bypass the requirement for transgenic
Sox2 expression.
We treated an Oct4::GFP-negative, partially reprogrammed
cell line (OKMS 6) with RepSox and performed global gene
expression analysis at 10, 24, and 48 hr after the initiation of
treatment. To confirm that RepSox was inhibiting Tgf-b signaling
in this intermediate cell line, we investigated expression changes
in known Tgf-b-responsive genes after RepSox treatment. The
Inhibition of Differentiation genes Id1, Id2, and Id3 are repressed
by Tgf-b signaling in mESCs (Ying et al., 2003). After treating the
RepSox-responsive intermediate line OKM 10 with RepSox for
24 hr, we observed increased expression of Id1, Id2, and Id3
(Figure S9A).
One way that RepSox could function to replace transgenic
Sox2 would be to induce the expression of endogenous Sox2
or a Sox family member, such as Sox1 or Sox3, that can substi-
tute for it in reprogramming (Nakagawa et al., 2008). However,
we again did not observe a significant increase in the expression
of Sox1, Sox2, Sox3, or any of the remaining Sox family tran-
scription factors within the first 48 hr of RepSox treatment
(Figure S9B). Additionally, shRNA-mediated depletion of Sox1,
the most potent Sox family member other than Sox2 itself (Naka-
gawa et al., 2008), did not affect the rate of reprogramming in the
presence of RepSox (Figure S9C). These results show that
RepSox does not replace Sox2 by directly activating endoge-
nous Sox2 or other closely related genes.
Next, we more broadly investigated changes in transcription
factor expression after chemical treatment. We did not observeCean increase in endogenous Oct4 or Klf4 expression at early
time points after RepSox treatment. However, we found that
the expression of the homeodomain factor Nanog was among
the most increased after RepSox treatment. Relative to
untreated controls, Nanog transcription increased 4-fold within
24 hr and 10-fold after 48 hr of RepSox treatment (Figure 6A).
In contrast, we did not observe a rapid increase inNanog expres-
sion in twoOct4::GFP-negative intermediate cell lines that could
not be fully reprogrammed with RepSox (Figure S10). Therefore,
we hypothesized that RepSox might replace Sox2 by inducing
Nanog expression.
Because we had determined that inhibition of Tgf-b signaling
by several different small molecules and antibodies can replace
Sox2, we reasoned that if the increase in Nanog expression was
critical for Sox2 replacement, the alternative inhibitors of Tgf-b
signaling should also upregulate Nanog. To test this hypothesis,
we treated the RepSox-responsive cell lines with RepSox,
SB431542, or neutralizing antibodies and analyzed Nanog
expression after 48 hr. In all cases, Nanog expression was
strongly induced within 48–96 hr (Figure 6B).
If RepSox functions by increasing Nanog expression, then
a short pulse of RepSox should induce a persistent increase in
Nanog expression. To test this, we treated the RepSox-respon-
sive intermediate cell line OKM 10 with RepSox for 48 hr, with-
drew RepSox, and analyzed Nanog expression 48 hr later.
A control timepoint taken just beforeRepSoxwithdrawal showed
a significant increase in Nanog transcription (Figure 6C). Forty-
eight hours afterRepSox removal (96hr after the initiation of treat-
ment), Nanog expression continued to increase (Figure 6C).
If RepSox replaces Sox2 by increasing Nanog expression,
then a forced reduction of Nanog expression should inhibit or
even prevent reprogramming byRepSox. To test this hypothesis,
we transduced the RepSox-responsive cell line with a lentivirus
encoding a short-hairpin RNA specific for Nanog. The Nanog-
knockdown cells reprogrammed at a frequency that was
50-fold lower than cells transduced with an empty control vector
(Figure 6D). This effect was not caused by a general decrease in
reprogramming efficiency or differentiation of reprogrammed
cells due to Nanog depletion because MEFs transduced with
Oct4, Klf4, cMyc, Sox2, and the Nanog shRNA construct only
suffered a 50% loss in reprogramming efficiency (Figure 6D).
These results demonstrate that increased Nanog expression in
this context was only necessary for the replacement of Sox2 by
RepSox.
Previous reports have shown that chemical inhibition of Tgf-b
signaling by SB431542 increases bone morphogenetic protein
(Bmp) signaling in embryonic stem cells (Xu et al., 2008). It has
separately been shown that Bmp signaling in the presence of
Stat3 induces Nanog expression in mESCs (Suzuki et al.,
2006). The crosstalk between the Tgf-b and Bmp signaling path-
ways may be the result of a common requirement for Smad 4,
which mediates transcriptional events in the nucleus (Attisano
and Wrana, 2002). Similarly, we observed an increase in the
levels of phosphorylated Smad1 protein and Bmp-3 mRNA
in incompletely reprogrammed intermediates after RepSox(G)Nanog can substitute for Sox2 in defined-factor reprogramming of somatic fibroblasts. The error bars denote the standard error derived from quantification of
three separate wells of cells.
(H) Picture of a reprogrammed Oct4::GFP+ colony induced by Oct4, Klf4, cMyc, and Nanog transduction of MEFs. Scale bars represent 100 mm.ll Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc. 499
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A Tgf-b Inhibitor Replaces Sox2 in Reprogrammingtreatment (Figure S11). Furthermore, the stable, partially reprog-
rammed cells that responded to RepSox expressed the LIF
receptor at levels equivalent to those found in mESCs (Fig-
ure S12A). Expression of this receptor suggests that its down-
stream signal transduction pathway could be active in these
cells, thereby resulting in the presence of activated Stat3, which
is known to induce Nanog expression in conjunction with Bmp
signaling.
Because RepSox does not act on the initial population of
fibroblasts to replace Sox2, we would not expect Nanog to be
upregulated in RepSox-treated MEFs. Indeed, within 7 days of
transduction of MEFs with Oct4, Klf4, and cMyc, we did not
observe an increase in Nanog expression upon RepSox treat-
ment (Figure S12B). This may be explained in part by the obser-
vation that the LIF receptor, and thus activated Stat3, was not
highly expressed in these cells (Figure S12A). Because Nanog
plays a key role in maintaining ESCs in an undifferentiated state
(Chambers et al., 2003) and has been shown to enhance the
efficiency of reprogramming (Silva et al., 2006; Silva et al.,
2009; Yu et al., 2007), we decided to test whether Nanog could
directly replace Sox2 in reprogramming.
If RepSox replaces Sox2 by inducing Nanog expression, then
retroviral transduction of RepSox-responsive intermediate cells
(line OKM 10, Figures 5A and 5B) with Nanog should reprogram
them. When we transduced line OKM 10 with Sox2 as a control,
0.2% of the colonies expressed Oct4::GFP after 10 days, indi-
cating that reprogramming could be induced in this cell line by
Sox2 (Figures 6E and 6F). When we transduced the same stable
intermediate cell linewithNanog, it could also be reprogrammed,
with 0.3% of the colonies expressing Oct4::GFP+ after 10 days
(Figures 6E and 6F). In contrast, transductions with Oct4 or
Klf4 resulted in only 0.04% and 0% reprogramming efficiencies
(Figure 6F). These results suggest that Nanog can indeed func-
tionally replace Sox2 and induce reprogramming in these stable
intermediates formed from Oct4-, Klf4-, and cMyc-transduced
MEFs.
If Nanog can compensate for the omission of Sox2 in defined-
factor reprogramming, then MEFs transduced with Oct4, Klf4,
cMyc, and Nanog might be as efficiently reprogrammed as
MEFs transduced with Oct4, Klf4, cMyc, and Sox2. When we
transduced MEFs with Oct4, Klf4, cMyc, and Sox2 and scored
cultures 9 days later, an average of seven Oct4::GFP+ colonies
appeared for every 7500 cells plated (Figure 6G). A control trans-
duction with only Oct4, Klf4, and cMyc yielded no Oct4::GFP+
colonies (Figure 6G). Similar to the positive control transduction,
MEFs transduced with Oct4, Klf4, cMyc, and Nanog gave rise to
an average of five Oct4::GFP+ colonies for every 7500 cells
plated (Figures 6G, H). These colonies could be picked and
expanded and remained Oct4::GFP+ for at least five passages
(Figure S13A). Immunocytochemistry indicated that these cells
strongly activated Sox2 expression from the endogenous allele
(Figure S13B). Importantly, QPCR analysis demonstrated that
they also transcribed endogenous Oct4, Klf4, Nanog, and Rex1
(Figure S13C), indicating that a pluripotent gene expression
program had been established. Furthermore, transgene-specific
QPCR analysis showed that these cells had silenced the retro-
viral Oct4, Klf4, and cMyc transgenes (Figure S13D). Addition-
ally, Oct4-, Klf4-, cMyc-, and Nanog-reprogrammed cells could
readily form embryoid bodies in vitro (Figure S13E). However,500 Cell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inwe found that leaky expression of transgenic Nanog, which is
a potent inhibitor of ESC differentiation (Chambers et al., 2003;
Chambers et al., 2007), reduced the amount of differentiation
in vitro (Figure S13D). We anticipate that efficient differentiation
of cells created with Oct4, Klf4, cMyc, and Nanog will eventually
require the use of an excisable transgenic Nanog cassette to
completely remove ectopic Nanog expression. Although defini-
tive proof of the pluripotency of these cells will be required to
conclude that Nanog expression is sufficient for replacing Sox2
in defined factor reprogramming, our results suggest that this
may be the case. Taken together, our results demonstrate that
RepSox inhibition of Tgf-b signaling bypasses the need for
Sox2 in defined-factor reprogramming through the induction of
Nanog.
DISCUSSION
We have used a phenotypic chemical screen to identify
compounds that can replace the reprogramming transcription
factor Sox2 and have confirmed the mechanism by which the
most potent compound acts: RepSox replaces Sox2 by inhibit-
ing the broadly expressed Tgf-b signaling pathway (Attisano
andWrana, 2002) in cultures containing stable intermediate cells
that are trapped in a partially reprogrammed state. This inhibition
in turn leads to sustained transcription of Nanog, through which
reprogramming is achieved in the absence of Sox2. These
results demonstrate the feasibility of replacing the central
reprogramming transgenes with small molecules that modulate
discrete cellular pathways or processes rather than by globally
altering chromatin structure. Furthermore, they show that the
mechanisms by which these molecules act in reprogramming
can be distinct from those of the factor(s) that they replace.
Importantly, and unlike many other studies (Mikkelsen et al.,
2008; Shi et al., 2008a; Shi et al., 2008b; Utikal et al., 2009),
the approach that we report here for replacing Sox2 did not
rely on procurement of a highly specialized or rare cell type
that already expresses Sox2. Furthermore, treatment with
RepSox allowed the generation of iPSCs from both adult and
embryonic fibroblasts with a frequency comparable to that of
transduction with Sox2. Thus, reprogramming efficiency does
not need to be compromised by small-molecule replacement
of transgenic factors.
We observed that instead of working on the initial fibroblast
population to replace Sox2, RepSox acts on cellular intermedi-
ates formed by overexpression of Oct4, Klf4, and cMyc. Without
RepSox treatment, these intermediates are trapped in an unpro-
ductive state. Unlike previously described partially reprog-
rammed cells (Mikkelsen et al., 2008; Silva et al., 2009), the
RepSox-responsive intermediates could not be reprogrammed
with AZA or 2i treatment, suggesting that they are distinct. In
addition,we found thatRepSoxdoesnot target anyof the kinases
inhibited by the 2i cocktail, indicating that it works through
a different mechanism. Furthermore, four-factor intermediates
that reprogram with RepSox treatment are not responsive to
AZA, indicating that they also are distinct.
These findings demonstrate that reprogramming can proceed
in a stepwise fashion through different intermediates. Just as in
a geographical setting in where there are multiple routes to travel
from point A to point B, there exist different intermediate statesc.
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A Tgf-b Inhibitor Replaces Sox2 in Reprogrammingor ‘‘way stations’’ that somatic cells can transit through on the
way to complete reprogramming. Interestingly, although our
results indicate that defined-factor reprogramming with Oct4,
Klf4, cMyc, and Sox2 can occur in the absence of Nanog, its
induction is required for chemical reprogramming of both our
RepSox-responsive intermediates and the recently described
2i-responsive intermediates made from Oct4, Klf4, and cMyc
transduction of cells that express Sox2 endogenously (Silva
et al., 2009). This indicates that commonalities can exist in the
reprogramming routes used by some sets of distinct intermedi-
ates.
Originally, we found it surprising that Nanog was not included
in the initial set of defined reprogramming factors (Takahashi and
Yamanaka, 2006) given its critical role in maintaining pluripo-
tency in ESCs (Boyer et al., 2005; Chambers et al., 2003) and
its ability to stimulate reprogramming by cell fusion (Silva et al.,
2006). However, Takahashi and Yamanaka reported that
a combination of nine factors that included Oct4, Klf4, cMyc,
and Nanog, but not Sox2, generated iPSC colonies at a detect-
able rate (Takahashi and Yamanaka, 2006). This combination of
factors included other genes that may have inadvertently
lowered the rate of reprogramming, thereby causing the combi-
nation ofOct4, Klf4, cMyc, andNanog to be overlooked. Consis-
tent with these data, work by Niwa and coworkers with inducible
Sox2 null mESCs demonstrated that Sox2 is dispensable for
modulation of the Oct-Sox enhancers that regulate pluripotent-
specific gene expression and instead mainly governs pluripo-
tency in ESCs by regulating the expression ofOct4 through other
factors (Masui et al., 2007). Therefore, it is possible that Nanog
may alleviate the requirement for Sox2 in reprogramming by
stimulating or maintaining Oct4 expression. Indeed, Nanog is
capable of maintaining Oct4 expression in mESCs (Chambers
et al., 2003). Thompson and coworkers also reported that
NANOG expression enhanced the reprogramming of human
fibroblasts but that it was not able to replace SOX2 in the pres-
ence of onlyOCT4 and LIN-28 (Yu et al., 2007). This may indicate
thatKlf4 is required forNanog to function optimally in reprogram-
ming and suggests that either they or the genes they modulate
interact during the reprogramming process.
It is well known that 90% of genes with promoters bound by
OCT4 and SOX2 in human ESCs are also bound by NANOG
(Boyer et al., 2005). Our result suggests that either Nanog or
Sox2 may be sufficient for collaborating with Oct4 to modulate
these genes and drive reprogramming. Although Nanog is not
required for pluripotency, it safeguards ESCs against neuroecto-
dermal and, to a more limited extent, mesodermal differentiation
(Chambers et al., 2007; Vallier et al., 2009). Therefore, it is
possible that Nanog functions in reprogramming by repressing
differentiation signals, thereby assisting in the transition to an
undifferentiated state.
Interestingly, we found that RepSox is also able to functionally
replace cMyc in reprogramming. Together, these observations
highlight the fact that small molecules may functionally replace
reprogramming transcription factors at either early or late
stages of the process and that they can act by different mech-
anisms—by inducing the expression of the gene itself, a closely
related family member, or an unrelated gene that can function-
ally rescue the omission of the reprogramming transcription
factor.CeOur observation that a 1 day treatment with RepSox can
relieve the requirement for transgenic Sox2 indicates that unlike
reprogramming with transgenic Oct4, Klf4, and Sox2, in which
each transgene must be expressed for several days (Sridharan
et al., 2009; Stadtfeld et al., 2008), small molecules can act as
switches to induce stable gene expression changes that
promote the completion of reprogramming. This could be an
important concept for achieving purely chemical reprogramming
given that our data show that chemicals such as RepSox can
affect cellular processes differently depending on the timing of
administration.
As we have shown here, there need not always be a discrete,
one-to-one mapping between the functions of the reprogram-
ming factors and their chemical replacements. Thus, it may be
that reiterative screening in the presence of Sox2 replacement
molecules will be required for identifying compounds that can
act in concert to replace Oct4 and Klf4. However, it will be of
significant interest to determine whether the novel reprogram-
ming compounds we have identified can collaborate with those
previously described (Marson et al., 2008; Shi et al., 2008a; Silva
et al., 2008) to replace the remaining reprogramming genes,
opening a route to purely chemical reprogramming.
EXPERIMENTAL PROCEDURES
Retroviral Infection
Retroviral infections were performed as previously described with the pMXs
vector (Takahashi et al., 2007a). MEFs were infected with two to three pools
of viral supernatant during a 72 hr period. The first day that viral supernatant
was added was termed ‘‘day 1 post-infection.’’ For quantification,Oct4::GFP+
colonies were counted at day 30 postinfection unless otherwise stated. All
animal research was performed under the oversight of the Office of Animal
Resources at Harvard University.
Small-Molecule Screens
On day 4 postinfection, infected MEFs were trypsinized and reseeded on irra-
diated feeders in 96-well plates at 2000 cells/well and cultured in mouse ESC
media (Knockout DMEM,15% Hyclone FBS, L-glutamine, penicillin/strepto-
mycin, nonessential amino acids, b-mercaptoethanol, and 1000 U/ml LIF).
The next day, compound stock solutions diluted in DMSO and VPA (Sigma)
were added at a final concentration of 1 mM and 2 mM, respectively. VPA
was removed after 1 week, and the compound was reapplied every other
day with each media change. Plates were scored for GFP+ colonies after
11 days of compound treatment.
Quantification of Oct4::GFP+ iPSCs Generated with Small-Molecule
Hit Compounds, SB431542, and Tgf-b Antibodies
Retroviral infection and compound or antibody treatment was performed as in
the original chemical screen. For quantification of the numbers of GFP+ colo-
nies produced in different conditions, the number of colonies in each well was
counted and at least two different wells were counted and averaged. Concen-
trations of compounds and antibodies were as follows: VPA (Sigma), 2 mM;
RepSox (Calbiochem), 25 mM or 1 mM as noted; E-616451 (Calbiochem),
3 mM; EI-275 (Biomol), 3 mM; SB431542 (Sigma), 25 mM or 2 mM as noted;
TgfbII-specific antibody (R&D Systems, AB-12-NA), 10 mg/ml; and pan-Tgfb
antibody (R&D Systems, AB-100-NA), 10 mg/ml. Unless otherwise noted,
all chemical treatments were continuous from initial administration at day
4–5 postinfection until GFP+ colonies were scored at day 30 posttransduction.
Fresh chemical was added at each media change.
Chemical Reprogramming of Stable Intermediate Cell Lines
Oct4::GFP-negative colonies in Oct4, Klf4, and cMyc or Oct4-, Klf4-, cMyc-,
and Sox2-infectedMEF cultures were picked and plated on irradiated feeders,
and single colonies were picked after 1 week. The resulting cell lines werell Stem Cell 5, 491–503, November 6, 2009 ª2009 Elsevier Inc. 501
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A Tgf-b Inhibitor Replaces Sox2 in Reprogrammingpassagedwith trypsin and grown inmESCmedia on feeders until passage 4, at
which time they were treated with RepSox (25 mM), AZA (500 mM), or both for
48 hr. For 2i treatment, CHIR99021 (Stemgent) was used at 3 mM and
PD0325901 (Stemgent) was used at 1 mM. Oct4::GFP+ colonies were scored
12 days after the beginning of chemical treatment. Treatmentswere performed
in mESC media containing FBS unless otherwise noted.
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figures, and 2 tables and can be found with this article online at http://www.
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